指南与共识脊柱关节炎

中轴型脊柱关节炎患者对肿瘤坏死因子抑制剂使用推荐的依从性及其5年随访影响

Adherence to recommendations for the use of anti-tumour necrosis factor and its impact over 5 years of follow-up in axial spondyloarthritis.
指南 / 共识 · Rheumatology (Oxford) · 2018-01-01

基于DESIR早期中轴型脊柱关节炎队列前5年随访,分析708例患者对ASAS 2003/2006、2016及欧洲药品管理局关于TNFα阻滞剂启动与继续使用推荐的依从性。启动推荐依从比例分别为62.15%、54.94%和47.32%,继续使用推荐依从比例分别为47.37%和49.39%。依从推荐者5年内BASFI更低、SF-36更高、病假天数更少。

要点

  • TNFα阻滞剂启动推荐依从率:ASAS 2003/2006为62.15%,ASAS 2016为54.94%,欧洲药品管理局为47.32%。
  • TNFα阻滞剂继续使用推荐依从率:ASAS 2003/2006为47.37%,ASAS 2016为49.39%。
  • 依从启动和继续使用推荐者5年内BASFI更低、SF-36更高、病假天数更少。

核心结论

  • 不足50%的患者TNFα阻滞剂启动和继续使用与推荐一致,但依从这些推荐可带来更好的功能结局和更少的病假天数。

研究设计与样本

  • 分析DESIR早期中轴型脊柱关节炎队列前5年随访数据,共708例患者,评估对ASAS 2003/2006、2016及欧洲药品管理局TNFα阻滞剂启动与继续使用推荐的依从性。

主要发现

  • TNFα阻滞剂启动依从ASAS 2003/2006推荐者440例(62.15%),依从ASAS 2016推荐者389例(54.94%),依从欧洲药品管理局推荐者335例(47.32%)。
  • TNFα阻滞剂继续使用依从ASAS 2003/2006推荐者为47.37%,依从ASAS 2016推荐者为49.39%。
  • 5年随访中,依从TNFα阻滞剂启动和继续使用推荐的患者BASFI更低、SF-36更高、病假天数更少。

关键数值与推荐

  • TNFα阻滞剂启动依从定义为:符合启动条件时开始治疗,或不符合启动条件时未开始治疗。
  • TNFα阻滞剂继续使用依从定义为:符合继续使用条件时继续治疗,或不符合继续使用条件时停止治疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To describe adherence to recommendations for TNFα blocker (TNFb) initiation and continuation in early axial Spondyloarthropathy (axSpA); and to evaluate the impact of adherence to these recommendations over 5 years of follow-up in the DEvenir des Spondyloarthrites Indifférenciées Récentes (DESIR) cohort. METHODS: The first 5 years of follow-up of the DESIR early axSpA cohort were analysed. We evaluated adherence to Assessment of SpondyloArthritis International Society (ASAS) 2003/2006, 2016 and European Medicines Agency recommendations in axSpA patients for: TNFb initiation (patients were adherent if they either commenced TNFb therapy when they met the conditions for initiation or if they did not commence TNFb therapy when conditions were not met) and; TNFb continuation (either when they continued TNFb therapy when conditions to continue were met or when they discontinued when conditions were not met). The impact of adherence to these recommendations on functional disability, quality of life and sick-leave days over 5 years was explored. RESULTS: A total of 708 patients were analysed: 440 (62.15%), 389 (54.94%) and 335 (47.32%) were considered adherent to ASAS 2003/2006, 2016 and European Medicines Agency recommendations for TNFb initiation, respectively. Adherence to 2003/2006 and 2016 recommendations for TNFb continuation was observed in 47.37 and 49.39% of patients, respectively. According to over 5 years of follow-up, better outcomes (lower BASFI, higher SF-36 and fewer days of sick leave) were found in patients adhering to recommendations for TNFb commencement and continuation. CONCLUSION: Less than 50% of patients were treated in agreement with recommendations for TNFb initiation and continuation. Nevertheless, adherence to such recommendations leads to better functional outcomes and fewer days of sick leave, according to long-term follow-up.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. López-Medina C, Dougados M, Collantes-Estévez E, et al. Adherence to recommendations for the use of anti-tumour necrosis factor and its impact over 5 years of follow-up in axial spondyloarthritis. Rheumatology (Oxford). 2018. PMID: 29474666. doi:10.1093/rheumatology/kex514

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。